XML 29 R18.htm IDEA: XBRL DOCUMENT v3.8.0.1
12. Restructuring Costs (Notes)
3 Months Ended
Mar. 31, 2018
Restructuring Costs [Abstract]  
Restructuring and Related Activities Disclosure [Text Block] 12.    RESTRUCTURING COSTS

Restructuring Costs for European Reorganization

In May, 2016, we announced that we would take certain actions in our Europe geographic region designed to better align expenses to our revenue and gross margin profile and position us for improved operating performance. These actions, aligned with creation and evolution of our organization structure and coordinated with the implementation of our global single instance ERP platform, are expected to be incurred through 2019. As a result, we recorded less than $0.1 million of adjustments in restructuring charges related to severance and other employee benefits for the three months ended March 31, 2018. The liability of $5.4 million as of March 31, 2018 consisted of $5.3 million recorded in Accrued payroll and employee benefits and $0.1 million recorded in Other long-term liabilities in the Condensed Consolidated Balance Sheets. The amounts recorded reflected in Cost of goods sold and in Selling, general and administrative expense in the Condensed Consolidated Statements of Income for the three months ended March 31, 2018 were both less than $0.1 million.

The following table summarizes the activity of our European reorganization restructuring reserves for severance (in millions):
 
 
Life Science
 
Clinical Diagnostics
 
Total
Balance as of January 1, 2018
 
$
2.2

 
$
4.1

 
$
6.3

Charged to expense
 

 

 

Adjustment to expense
 

 

 

Cash payments
 
(0.3
)
 
(0.7
)
 
(1.0
)
Foreign currency translation losses
 

 
0.1

 
0.1

Balance as of March 31, 2018
 
$
1.9

 
$
3.5

 
$
5.4




Restructuring Costs for Termination of a Diagnostics Research and Development Project

In December 2017, we announced the termination of a diagnostics research and development project in Europe, which is included in our Clinical Diagnostics segment's results of operations. As a result, we recorded less than $0.1 million of adjustments in restructuring charges related to severance and employee benefits, and exit costs for the three months ended March 31, 2018. The amounts recorded reflected in Cost of goods sold, in Selling, general and administrative expense, and in Research and development expense in the Condensed Consolidated Statements of Income for the three months ended March 31, 2018 were all less than $0.1 million. The liability of $13.1 million as of March 31, 2018 consisted of $10.0 million recorded in Accrued payroll and employee benefits and $3.1 million recorded in Other current liabilities in the Condensed Consolidated Balance Sheets.

The following table summarizes the activity for the termination of the diagnostics research and development project restructuring reserves for severance and exit costs (in millions):

 
 
2018
Balance as of January 1
 
$
14.1

Charged to expense
 

Adjustment to expense
 

Cash payments
 
(1.3
)
Foreign currency translation losses
 
0.3

Balance as of March 31
 
$
13.1